Alzheimer's AAIC Video Interview: Denali Therapeutics

from Scrip Podcasts · host Norstella

Denali CEO Ryan Watts talks about the company's TransportVehicle platform and how it can open up delivery of a wide range of drug cargoes into the brain. Its first approved therapy is Avlayah for Hunter Syndrome, with tau and beta-amyloid targeting assets for Alzheimer's in development.

Episode metadata supplied by the publisher feed · Published Jul 20, 2026

Embed this episode

Attribution link and audio player

Ready to play

Alzheimer's AAIC Video Interview: Denali Therapeutics

0:00 6:39

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Scrip Podcasts?

This episode is 6 minutes long.

When was this Scrip Podcasts episode published?

This episode was published on July 20, 2026.

Can I download this Scrip Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!